Health Care Analysis

, Volume 11, Issue 4, pp 279–286 | Cite as

Italian Drug Policy: Ethical Aims of Essential Assistance Levels

  • Alessandra Bernardi
  • Renzo Pegoraro
Article

Abstract

In 2001 the Italian Government defined Essential Assistance Levels (LEA), which can be considered as an important step forward in the health care system. The Italian health care system would provide payment of essential and uniform aid services in order to safeguard many values such as human dignity, personal health, equal assistance and good health practices. The Ministry of Health has worked to rationalize the National Formulary and to define evaluation methods for drugs in order to choose what to reimburse without penalizing the rights of the individual and society.

This paper describes how this job of rationalization was done and tries to illustrate the choices made in Italy by the use of two meaningful examples (statins and rivastigmine).

Essential Assistance Levels (LEA) statins rivastigmine Italian drug policy ethical aims pharmaceutical expenditure 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Atella, V. (2000) Drug Cost Containment Policies in Italy: Are They Really Effective in the Long-Run? The Case of Minimum Reference Price. Health Policy 50, 197-218.Google Scholar
  2. Begaud, B., Bergman, U., Eichler, H. G., Leufkens, H. G., and Meier, P. J. (2000) Drug Reimbursement: Indicators of Inappropriate Resource Allocation. British Journal of Clinical Pharmacology 54, 528-534.Google Scholar
  3. Braga, M., and Cislaghi, C. (2000) The Evaluation of Efficacy and Efficiency in the Health Care Sector: Separate or Integrated Moments? Annali di Igiene 14, 409-418.Google Scholar
  4. Fattore, G., and Jommi, C. (2000) The New Pharmaceutical Policy in Italy. Health Policy 46, 21-41.Google Scholar
  5. Pavenik, N. (2000) Do Pharmaceutical Price Respond to Potential Patient Out-of-Pocket Expenses? RAND Journal of ECONOMICS 33, 469-487.Google Scholar
  6. Rice, N., and Smith, P. C. (2000) Capitation and Risk Adjustment in Health Care. Health Care Management Science 3, 73-75.Google Scholar
  7. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M., Wun, C. C., Davis, B. R., and Braunwald, E. (2000) The Effect of Pravastatin on Coronary Events After Myocardical Infarction in Patients With Average Cholesterol Levels. Cholesterol and Recurrent Events Trial Investigators. New England Journal of Medicine 335, 1001-1009.Google Scholar
  8. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., and Packard, C. J., The West of Scotland Coronary Prevention Study Group. (2000) Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. New England Journal of Medicine 333, 1301-1307.Google Scholar
  9. The Long Term Interventions With Pravastatin in Ischemic Disease (LIPID) Study Group. (2000) Prevention of Cardiovascular Events and Death With Pravastatin in Patients With Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. New England Journal of Medicine 339, 1349.Google Scholar
  10. The Scandinavian Simvastatin Survival Study Group. (2000) Randomised Trial of Cholesterol Lowering in 4.444 Patients With Coronary Heart Disease. The Scandinavian Simvastatin Survival Study. Lancet 344, 1383.Google Scholar
  11. Trabucchi, M. (2000) An Economic Perspective on Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology 12, 29-38.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Alessandra Bernardi
    • 1
  • Renzo Pegoraro
    • 1
  1. 1.Fondazione LanzaPadovaItaly

Personalised recommendations